Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth

The caller terms outlook comes connected Alnylam Pharmaceuticals announcing strategical priorities for the year, including achieving gross of $5.1 billion, exceeding the statement estimation of $4.7 billion. While determination person been concerns astir November performance, it was mostly affected by one-time factors, including less selling days. In the agelong term, the institution is targeting 25% compound yearly maturation complaint done 2030, which aligns with gross of $11.2 billion.

On the different hand, Cantor Fitzgerald has reiterated its Neutral standing connected Alnylam Pharmaceuticals. The cautious outlook comes connected Amvuttra cardiomyopathy income slowing down successful November but rebounding successful December. The institution expects Amvuttra’s nett terms to diminution by mid-single digits successful 2026. The income patterns and pricing strategy supply discourse for the probe firm’s neutral stance.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) develops innovative medicines utilizing RNA interference (RNAi) to “silence” disease-causing genes, acting arsenic a pioneer successful this revolutionary tract to make treatments for uncommon and prevalent genetic, metabolic, cardiovascular, and neurological diseases.

While we admit the imaginable of ALNY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.